Cargando…

Brief review on repurposed drugs and vaccines for possible treatment of COVID-19

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of the pandemic coronavirus disease 2019 (Covid-19) has claimed more than a million lives. Various in silico, in vitro, and in vivo studies are being conducted to understand the effect of SARS-CoV-2 on the cellular met...

Descripción completa

Detalles Bibliográficos
Autores principales: De, Priyasha, Chakraborty, Ishita, Karna, Bhargavi, Mazumder, Nirmal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905377/
https://www.ncbi.nlm.nih.gov/pubmed/33639193
http://dx.doi.org/10.1016/j.ejphar.2021.173977
_version_ 1783655101328523264
author De, Priyasha
Chakraborty, Ishita
Karna, Bhargavi
Mazumder, Nirmal
author_facet De, Priyasha
Chakraborty, Ishita
Karna, Bhargavi
Mazumder, Nirmal
author_sort De, Priyasha
collection PubMed
description Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of the pandemic coronavirus disease 2019 (Covid-19) has claimed more than a million lives. Various in silico, in vitro, and in vivo studies are being conducted to understand the effect of SARS-CoV-2 on the cellular metabolism of humans and the various drugs and drug-targets that may be used. In this review, we discuss protein-protein interactions (PPIs) between viral and human proteins as well as viral targets like proteases. We try to understand the molecular mechanism of various repurposed antiviral drugs against SARS-CoV-2, their combination therapies, drug dosage regimens, and their adverse effects along with possible alternatives like non-toxic antiviral phytochemicals. Ultimately, randomized controlled trials are needed to identify which of these compounds has the required balance of efficacy and safety. We also focus on the recent advancements in diagnostic methods and vaccine candidates developed around the world to fight against Covid-19.
format Online
Article
Text
id pubmed-7905377
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-79053772021-02-25 Brief review on repurposed drugs and vaccines for possible treatment of COVID-19 De, Priyasha Chakraborty, Ishita Karna, Bhargavi Mazumder, Nirmal Eur J Pharmacol Review Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of the pandemic coronavirus disease 2019 (Covid-19) has claimed more than a million lives. Various in silico, in vitro, and in vivo studies are being conducted to understand the effect of SARS-CoV-2 on the cellular metabolism of humans and the various drugs and drug-targets that may be used. In this review, we discuss protein-protein interactions (PPIs) between viral and human proteins as well as viral targets like proteases. We try to understand the molecular mechanism of various repurposed antiviral drugs against SARS-CoV-2, their combination therapies, drug dosage regimens, and their adverse effects along with possible alternatives like non-toxic antiviral phytochemicals. Ultimately, randomized controlled trials are needed to identify which of these compounds has the required balance of efficacy and safety. We also focus on the recent advancements in diagnostic methods and vaccine candidates developed around the world to fight against Covid-19. Elsevier B.V. 2021-05-05 2021-02-25 /pmc/articles/PMC7905377/ /pubmed/33639193 http://dx.doi.org/10.1016/j.ejphar.2021.173977 Text en © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review
De, Priyasha
Chakraborty, Ishita
Karna, Bhargavi
Mazumder, Nirmal
Brief review on repurposed drugs and vaccines for possible treatment of COVID-19
title Brief review on repurposed drugs and vaccines for possible treatment of COVID-19
title_full Brief review on repurposed drugs and vaccines for possible treatment of COVID-19
title_fullStr Brief review on repurposed drugs and vaccines for possible treatment of COVID-19
title_full_unstemmed Brief review on repurposed drugs and vaccines for possible treatment of COVID-19
title_short Brief review on repurposed drugs and vaccines for possible treatment of COVID-19
title_sort brief review on repurposed drugs and vaccines for possible treatment of covid-19
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905377/
https://www.ncbi.nlm.nih.gov/pubmed/33639193
http://dx.doi.org/10.1016/j.ejphar.2021.173977
work_keys_str_mv AT depriyasha briefreviewonrepurposeddrugsandvaccinesforpossibletreatmentofcovid19
AT chakrabortyishita briefreviewonrepurposeddrugsandvaccinesforpossibletreatmentofcovid19
AT karnabhargavi briefreviewonrepurposeddrugsandvaccinesforpossibletreatmentofcovid19
AT mazumdernirmal briefreviewonrepurposeddrugsandvaccinesforpossibletreatmentofcovid19